Bringing the fundamentals into focus…
Back to Castle Biosciences, Inc.
How Castle Biosciences, Inc. stacks up
CSTL · against 458 other Healthcare companies of similar size
Profitability
31/ 100
Below the middle of the pack.
Ranked #324 of 459 · scores higher than 29% of peers
Bars: peers in each 10-point band of the profitability score50 peers with a profitability score of 30–39, including CSTL · Click a bar to see the companies
Why profitability scores 31?
Weighted metrics compared with all Healthcare companies.Mainly because of its operating margin, return on invested capital and return on assets, which are weaker than most Healthcare peers.
- a thinner operating margin: weaker than 74% of peers. Operating margin: -9.0% vs peer median 7.1%
- a lower return on invested capital: weaker than 72% of peers. Return on invested capital: -6.1% vs peer median 4.7%
- a lower return on assets: weaker than 68% of peers. Return on assets: -3.5% vs peer median 1.7%
Metric by metric
Position: dot = CSTL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CSTL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 435 reported | -6.1% | 4.5% | 27% | 33% | |
| Operating marginHigher is better · 429 reported | -9.0% | 6.8% | 24% | 33% | |
| Return on assetsHigher is better · 446 reported | -3.5% | 1.5% | 30% | 33% | |
| Return on equityHigher is better · 429 reported | -4.2% | 2.9% | 37% | Context only | |
| Gross marginHigher is better · 478 reported | 77.3% | 47.7% | 86% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around CSTL| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 3 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 3 | 595M USD | 99 | 97 | |
| 3 | 11.2B DKK (≈$1.7B) | 99 | 59 | |
| 319 | 2.0B USD | 32 | 44 | |
| 319 | 1.6B USD | 32 | 29 | |
| 324 | 8.9B HKD (≈$1.1B) | 31 | 61 | |
| 324 | 4.2B CNY (≈$583M) | 31 | 40 | |
| 324 | 1.1B USD | 31 | 43 | |
| 324 | 1.3B USD | 31 | 20 | |
| 328 | 7.1B CNY (≈$993M) | 30 | 27 | |
| 328 | 4.0B CNY (≈$561M) | 30 | 33 | |
| 328 | 6.8B CNY (≈$946M) | 30 | 21 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score